Cargando…

Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma

Patients with resectable pancreatic ductal adenocarcinoma (PDAC) show differential prognosis after radical resection. Currently, cancer grading and surgical criteria depend heavily on imaging and anatomical diagnosis. It's essential to set up a model with reliable prognostic factors during the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaojie, Li, Shengnan, Liu, Lili, Hong, Jiahui, Zhao, Tiansuo, Gao, Chuntao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930410/ https://www.ncbi.nlm.nih.gov/pubmed/31892968 http://dx.doi.org/10.7150/jca.33767

Ejemplares similares

Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer
por: Li, Shengnan, et al.
Publicado: (2022)

Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma
por: Ermiah, Eramah, et al.
Publicado: (2022)

Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients With Resectable Pancreatic Ductal Adenocarcinoma
por: Chen, Tao, et al.
Publicado: (2015)

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
por: Lohneis, Philipp, et al.
Publicado: (2018)

SCF, Regulated by HIF-1α, Promotes Pancreatic Ductal Adenocarcinoma Cell Progression
por: Gao, Chuntao, et al.
Publicado: (2015)

Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I–III pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Zou, Yiping, et al.
Publicado: (2023)

Coexpression of EGFR and CXCR4 Predicts Poor Prognosis in Resected Pancreatic Ductal Adenocarcinoma
por: Wu, Huanwen, et al.
Publicado: (2015)

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma
por: Li, Shuo, et al.
Publicado: (2019)

The effects of CYP24A1 on clinicopathological features and the prognosis of pancreatic ductal adenocarcinoma
por: Gao, Wei, et al.
Publicado: (2020)

Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocarcinoma
por: Hu, Beiyuan, et al.
Publicado: (2022)

Serum insulin‐like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma‐associated malnutrition and muscle wasting
por: Dong, Jie, et al.
Publicado: (2021)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma
por: Lee, Kyong Joo, et al.
Publicado: (2013)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression
por: Jin, Fanjie, et al.
Publicado: (2020)

Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression
por: Park, Sejun, et al.
Publicado: (2023)

Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis
por: MacCurtain, Benjamin M., et al.
Publicado: (2021)

Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma
por: Wang, Lili, et al.
Publicado: (2017)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection
por: Flis, Vojko, et al.
Publicado: (2016)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study
por: Dong, Qian, et al.
Publicado: (2014)

Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma
por: Leppänen, Joni, et al.
Publicado: (2018)

Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma
por: He, Chaobin, et al.
Publicado: (2018)

Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma
por: Agrawal, Shefali
Publicado: (2017)

Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort
por: Zhou, Guofeng, et al.
Publicado: (2017)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
por: Li, Tianjiao, et al.
Publicado: (2019)

Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
por: Buc, Emmanuel, et al.
Publicado: (2014)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition
por: Soweid, Assaad M.
Publicado: (2017)

Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma
por: Hu, Dingyuan, et al.
Publicado: (2019)

Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection
por: Sugawara, Toshitaka, et al.
Publicado: (2021)

UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept
por: Martinez-Useros, Javier, et al.
Publicado: (2017)

The Clinical Significance of CEA, CA19–9, and CA125 in Management of Appendiceal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma
por: Chen, Ru, et al.
Publicado: (2014)

Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma
por: Dong, Qian, et al.
Publicado: (2017)

The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification
por: Yang, Yefan, et al.
Publicado: (2022)

Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma
por: Suzuoki, M, et al.
Publicado: (2002)

Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
por: Saukkonen, Kapo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_41j09t2ta5o1k5don20tngntrn